Pasithea Therapeutics Corp. (KTTAW) Income towards Parent Company (2021 - 2026)

Pasithea Therapeutics has disclosed Income towards Parent Company across 6 years of filings, most recently posting -$5.3 million for Q2 2026.

• In Q2 2026, Income towards Parent Company fell 41.92% year-over-year to -$5.3 million; the TTM figure through Jun 2026 stood at -$21.3 million (down 58.22% YoY), while the FY2025 annual figure was -$20.4 million, down 46.91% from the prior year.
• Income towards Parent Company came in at -$5.3 million for Q2 2026 at Pasithea Therapeutics, down from -$2.9 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$1.9 million in Q1 2022 to a low of -$10.1 million in Q4 2025.
• Average Income towards Parent Company over 5 years is -$4.2 million, with a median of -$3.7 million recorded in 2023.
• Year-over-year, Income towards Parent Company plunged 1454.4% in 2022 and surged 40.09% in 2023.
• Over 5 years, Income towards Parent Company stood at -$8.5 million in 2022, then surged by 40.09% to -$5.1 million in 2023, then jumped by 37.85% to -$3.2 million in 2024, then plunged by 218.19% to -$10.1 million in 2025, then jumped by 47.84% to -$5.3 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were -$5.3 million in Q2 2026, -$2.9 million in Q1 2026, and -$10.1 million in Q4 2025.